Subscribe
clu
clu / iStockphoto.com
24 May 2018Americas

Fed Circuit sides with district court in UCB win against generics

Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

More on this story

Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB